Observational study / 2013
Lead released from microgravity-induced bone loss in astronauts is typically offset by low spacecraft environmental lead, leading to decreased blood lead levels.
Researchers modified a physiologically based pharmacokinetic model to assess blood lead levels (PbB) resulting from microgravity-accelerated bone loss and spacecraft drinking water lead concentrations (PbW). The model predicted that for an average American astronaut, Pb release from bone is offset by reduced ingested or inhaled environmental Pb, causing PbB to decrease when PbW is below approximately 9 µg/L. Measured PbB in astronauts before and after 6-month missions on the International Space Station (ISS), where PbW averages 0.6 µg/L compared to 5 µg/L at Johnson Space Center, supported these results. Most astronauts will not be adversely affected, though a small percentage with high bone lead could be at risk depending on individual bone loss rates.
Shows an association, not proof of cause and effect.
- Study type
- Pharmacokinetic modeling with observational pre- and post-flight data
- Who was studied
- Astronauts on 6-month stays on the International Space Station
- What was measured
- Blood lead levels (PbB) related to bone loss and spacecraft drinking water (PbW)
THE PAPER
Modeling of blood lead levels in astronauts exposed to lead from microgravity-accelerated bone loss.
Garcia HD, Hays SM, Tsuji JS. Aviat Space Environ Med, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.